Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer Inc Boulder

This publication has 27 references indexed in Scilit: